255 related articles for article (PubMed ID: 24797298)
1. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.
Sorror ML; Martin PJ; Storb RF; Bhatia S; Maziarz RT; Pulsipher MA; Maris MB; Davis C; Deeg HJ; Lee SJ; Maloney DG; Sandmaier BM; Appelbaum FR; Gooley TA
Blood; 2014 Jul; 124(2):287-95. PubMed ID: 24797298
[TBL] [Abstract][Full Text] [Related]
2. Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease.
Vaughn JE; Gooley T; Maziarz RT; Pulsipher MA; Bhatia S; Maloney DG; Sandmaier BM; Flowers ME; Storb R; Sorror ML
Br J Haematol; 2015 Nov; 171(3):411-6. PubMed ID: 26194447
[TBL] [Abstract][Full Text] [Related]
3. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.
Storb R; Gyurkocza B; Storer BE; Sorror ML; Blume K; Niederwieser D; Chauncey TR; Pulsipher MA; Petersen FB; Sahebi F; Agura ED; Hari P; Bruno B; McSweeney PA; Maris MB; Maziarz RT; Langston AA; Bethge W; Vindeløv L; Franke GN; Laport GG; Yeager AM; Hübel K; Deeg HJ; Georges GE; Flowers ME; Martin PJ; Mielcarek M; Woolfrey AE; Maloney DG; Sandmaier BM
J Clin Oncol; 2013 Apr; 31(12):1530-8. PubMed ID: 23478054
[TBL] [Abstract][Full Text] [Related]
4. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities.
Sorror ML; Maris MB; Storer B; Sandmaier BM; Diaconescu R; Flowers C; Maloney DG; Storb R
Blood; 2004 Aug; 104(4):961-8. PubMed ID: 15113759
[TBL] [Abstract][Full Text] [Related]
5. Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Willems E; Humblet-Baron S; Dengis O; Seidel L; Beguin Y; Baron F
Bone Marrow Transplant; 2010 Sep; 45(9):1442-8. PubMed ID: 20062090
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
8. Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning.
Flowers ME; Traina F; Storer B; Maris M; Bethge WA; Carpenter P; Appelbaum F; Storb R; Sandmaier BM; Martin PJ
Bone Marrow Transplant; 2005 Feb; 35(3):277-82. PubMed ID: 15558037
[TBL] [Abstract][Full Text] [Related]
9. Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study.
Ishida T; Hishizawa M; Kato K; Tanosaki R; Fukuda T; Takatsuka Y; Eto T; Miyazaki Y; Hidaka M; Uike N; Miyamoto T; Tsudo M; Sakamaki H; Morishima Y; Suzuki R; Utsunomiya A
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1731-9. PubMed ID: 24090597
[TBL] [Abstract][Full Text] [Related]
10. Age influences post-graft-versus-host disease non-relapse mortality in adults with acute graft-versus-host disease of varying severity following allogeneic hematopoietic cell transplant.
Nakane T; Fukuda T; Kanda J; Taniguchi S; Eto T; Ohashi K; Nakamae H; Kurokawa M; Mori T; Morishima Y; Nagamura-Inoue T; Sakamaki H; Atsuta Y; Murata M
Leuk Lymphoma; 2015; 56(8):2392-7. PubMed ID: 25629984
[TBL] [Abstract][Full Text] [Related]
11. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
12. Pretransplant conditioning with Campath-1H (alemtuzumab) in pediatric matched unrelated hematopoietic stem cell transplants: an institutional experience.
Nageswara Rao AA; Kumar R; Altaf S; Gourde JA; Rodriguez V; Khan SP
J Pediatr Hematol Oncol; 2012 Mar; 34(2):96-100. PubMed ID: 22146532
[TBL] [Abstract][Full Text] [Related]
13. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Aladağ E; Demiroğlu H; Büyükaşık Y; Göker H
Turk J Haematol; 2021 Jun; 38(2):138-144. PubMed ID: 32539316
[TBL] [Abstract][Full Text] [Related]
15. Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens.
Sala-Torra O; Martin PJ; Storer B; Traina F; Sorror ML; Storb R; Sandmaier BM; Flowers ME
Bone Marrow Transplant; 2008 May; 41(10):887-93. PubMed ID: 18209720
[TBL] [Abstract][Full Text] [Related]
16. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
17. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
18. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens.
Leisenring WM; Martin PJ; Petersdorf EW; Regan AE; Aboulhosn N; Stern JM; Aker SN; Salazar RC; McDonald GB
Blood; 2006 Jul; 108(2):749-55. PubMed ID: 16537799
[TBL] [Abstract][Full Text] [Related]
19. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors.
Guru Murthy GS; Kim S; Hu ZH; Estrada-Merly N; Abid MB; Aljurf M; Bacher U; Badawy SM; Beitinjaneh A; Bredeson C; Cahn JY; Cerny J; Diaz Perez MA; Farhadfar N; Gale RP; Ganguly S; Gergis U; Hildebrandt GC; Grunwald MR; Hashmi S; Hossain NM; Kalaycio M; Kamble RT; Kharfan-Dabaja MA; Hamilton BK; Lazarus HM; Liesveld J; Litzow M; Marks DI; Murthy HS; Nathan S; Nazha A; Nishihori T; Patel SS; Pawarode A; Rizzieri D; Savani B; Seo S; Solh M; Ustun C; van der Poel M; Verdonck LF; Vij R; Wirk B; Oran B; Nakamura R; Scott B; Saber W
JAMA Oncol; 2022 Mar; 8(3):404-411. PubMed ID: 35024768
[TBL] [Abstract][Full Text] [Related]
20. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.
El-Jawahri A; Li S; Antin JH; Spitzer TR; Armand PA; Koreth J; Nikiforow S; Ballen KK; Ho VT; Alyea EP; Dey BR; McAfee SL; Glotzbecker BE; Soiffer RJ; Cutler CS; Chen YB
Biol Blood Marrow Transplant; 2016 May; 22(5):910-8. PubMed ID: 26748160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
